Andra AP fonden Has $18.16 Million Stake in IQVIA Holdings Inc. $IQV

Andra AP fonden reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 22.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 94,005 shares of the medical research company’s stock after selling 27,400 shares during the period. Andra AP fonden’s holdings in IQVIA were worth $18,164,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of IQV. Korea Investment CORP acquired a new position in IQVIA in the second quarter valued at approximately $13,918,000. Deutsche Bank AG bought a new stake in IQVIA in the second quarter valued at approximately $143,074,000. BlackRock Inc. acquired a new stake in IQVIA during the 2nd quarter worth $2,811,292,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of IQVIA during the second quarter worth about $976,000. Finally, Pallas Capital Advisors LLC bought a new stake in IQVIA during the 2nd quarter worth approximately $1,552,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In related news, insider W. Richard Staub sold 5,500 shares of IQVIA stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. The trade was a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 15,581 shares of company stock valued at $3,796,021. Corporate insiders own 1.70% of the company’s stock.

IQVIA Stock Up 0.5%

IQV stock traded up $1.22 during midday trading on Tuesday, reaching $271.10. 200,371 shares of the company’s stock traded hands, compared to its average volume of 1,736,111. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $273.88. The company has a market cap of $44.62 billion, a price-to-earnings ratio of 33.66, a P/E/G ratio of 2.28 and a beta of 1.18. The firm’s fifty day moving average price is $243.93 and its 200-day moving average price is $200.29.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IQV. Robert W. Baird raised their price objective on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Barclays reiterated an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, Royal Bank Of Canada upped their target price on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $248.00.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.